Review of NICE Technology Appraisal Guidance No 101 Docetaxel for the treatment of hormone refractory prostate cancer

As you may be aware the planned date for review of the above guidance was June, 2009.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to update the guidance.

The Institute has carried out a search for information relevant to this appraisal, and has found that to the best of its knowledge, no new evidence has been published that would have a material effect on the original guidance.  However, we are aware of several clinical trials which are due to be completed throughout 2011. Consequently we propose that we reconsider an update to the guidance in June 2013, which will allow this research to be available.

Please note all comments received will be published on the Institute’s website when a decision has been made.

June 2009